Treatment of postmenopausal osteoporosis with odanacatib

Abstract

Introduction: The market of antiosteoporosis drugs has been declining in recent years, possibly in part due to the publicity around adverse events observed with bisphosphonates. Also, the proportion of patients with clinical fracture who receive adequate treatment remains low. So there are still unmet needs in this field. Odanacatib is a cathepsin K inhibitor currently being developed for the treatment of postmenopausal osteoporosis that could be an advance in this context.

Areas covered: Odanacatib is a bone resorption inhibitor, but it preserves some degree of bone formation, which differentiates this new family of drugs from existing therapies. Odanacatib increases bone mineral density at the spine and hip, improves estimated bone strength using finite element analysis at the spine and hip as well as at the distal tibia and radius. The safety profile has been satisfactory so far. A robust antifracture efficacy has been announced when the Phase III pivotal trial was terminated after interim analysis, but we do not yet have access to the complete results.

Expert opinion: Odanacatib may have an important role in future guidelines if it provides a substantial advantage compared to the effective and inexpensive current generic drugs, in terms of antifracture efficacy or safety.

Keywords::

• cathepsin K
• fracture
• odanacatib
• osteoporosis

Declaration of interest

R Chapurlat has received research funding from Merck, Amgen, Servier and Warner-Chilcott; he has received speaker fees from Chugai-Roche, Pfizer, Servier, Eli Lilly; advisory boards: Amgen, Bioiberica, Merck, Novartis. Specifically relevant to this article, he has been an investigator in several clinical trials of odanacatib.